Medication info
Tugenonjeong 5/16 mg

Tugenonjeong 5/16 mg

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tabletCandesartan Cilexetil›16mg / 1 tablet
Manufacturer / importer
Dong-A ST Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets (10 tablets/PTP x 3)
Approval status
Active

MFDS item code 201803501 · Approved 2018.08.28

Summary

Main use
Treatment of hypertension and heart failure; improvement of dyslipidemia; suppression of atherosclerosis progression and cardiovascular risk
Who takes it
Adults · Children
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the effects and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with particular caution in patients at increased risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those undergoing hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: An initial dose of 4 mg once daily is recommended. Double the dose at intervals of at least 2 weeks and, based on the patient's tolerability, increase it to a maximum of 32 mg once daily. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue the diet throughout treatment. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score exceeding 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.
Child dose
Candesartan cilexetil Essential hypertension: Safety and efficacy have not been established in adolescents and children 18 years of age or younger. Heart failure: Safety and efficacy have not been established in adolescents and children 18 years of age or younger.

Ingredients

Manufacturer
Dong-A ST Co., Ltd.

Efficacy & effects

Treatment of hypertension and heart failure; improvement of dyslipidemia; suppression of atherosclerosis progression and cardiovascular risk

  • Essential hypertension
  • left ventricular systolic dysfunction
  • hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary artery disease
View approved original text

This medicine is applied to patients using two drugs, Candesartan Cilexetil and Rosuvastatin. Candesartan Cilexetil is mainly used in patients with essential hypertension or heart failure with left ventricular dysfunction, especially when the use of ACE inhibitors is difficult or additional treatment is required. Meanwhile, Rosuvastatin is used as an adjunct to patients with hypercholesterolemia or mixed dyslipidemia when dietary control is not sufficient, and it also helps in the treatment of homozygous familial hypercholesterolemia and dysbetalipoproteinemia. Additionally, Rosuvastatin contributes to reducing the risk of stroke, myocardial infarction, and vascular reintervention in high-risk cardiovascular disease patients. By using both drugs together, cardiovascular health can be effectively improved through the management of blood pressure and blood cholesterol.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the effects and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with particular caution in patients at increased risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those undergoing hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: An initial dose of 4 mg once daily is recommended. Double the dose at intervals of at least 2 weeks and, based on the patient's tolerability, increase it to a maximum of 32 mg once daily. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue the diet throughout treatment. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score exceeding 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Child dose

Candesartan cilexetil Essential hypertension: Safety and efficacy have not been established in adolescents and children 18 years of age or younger. Heart failure: Safety and efficacy have not been established in adolescents and children 18 years of age or younger.

Precautions

This medication may cause serious harm to the fetus and newborn when taken during pregnancy, so it should be discontinued immediately if pregnancy is confirmed. Patients with a known allergy to this medicine or its components should not take it. It should not be administered to patients with severely impaired liver function, active liver disease, or severe kidney disease. Women of childbearing potential should practice appropriate contraception and should only take this medication after fully understanding the risks, even if the likelihood of pregnancy is low. This medication should be used cautiously in the elderly, patients with hyperkalemia, and those with mild to moderate hepatic impairment, requiring regular blood tests and liver function checks. If symptoms of musculoskeletal disorders such as muscle pain or weakness occur, patients should consult a doctor immediately, and in severe cases, treatment should be discontinued. This medicine may interact with other antihypertensive agents, diuretics, certain antibiotics, etc., so patients must inform their doctor or pharmacist about any other medications they are taking. During treatment, excessive alcohol should be avoided, and patients with liver or kidney function abnormalities should have regular check-ups. It is preferable for pregnant or breastfeeding women to avoid using this medicine, and if unavoidable, breastfeeding should be discontinued. Safety and efficacy have not been established for children, so it is not recommended. In case of overdose, symptoms such as hypotension and dizziness may occur, necessitating immediate medical attention. Caution is needed when driving or operating machinery as dizziness due to blood pressure lowering may occur. Keep this medication out of the reach of children, and it is not recommended to transfer medicines from the original container to another.

Side effects

Headache, nasopharyngitis, localized infection, fatigue, generalized pruritus, dermatitis, itching, joint stiffness, limb pain, photophobia, dyspepsia, elevated blood sugar, decreased serum sodium, hand fracture, hypoglycemia, nephrolithiasis, cough, headache, itching, nausea, dizziness, postural dizziness, miliaria, periodontitis, chest discomfort, inflammation, foreign body sensation, musculoskeletal pain, neck pain, cataract, elevated blood sugar, decreased serum sodium, hand fracture, hypoglycemia, nephrolithiasis, cough, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, constipation, nausea, abdominal pain, diarrhea, thrombocytopenia, jaundice, hepatitis, liver dysfunction, vascular edema, elevated serum and urine myoglobin, rhabdomyolysis, arthralgia, low back pain, renal impairment, acute renal failure, fever, dyspnea, abnormal chest X-ray, interstitial pneumonia, shock, syncope, loss of consciousness, paralysis, hypertonia, syncope, facial flushing, weight gain, facial edema, polydipsia, sleep disorders, decreased libido, memory loss, loss of appetite, increased appetite, tinnitus, dysgeusia, erectile dysfunction, elevated ALT, elevated CK, numbness, paresthesia, generalized pain, muscle cramps, gout, severe skin adverse reaction, Stevens-Johnson syndrome, eosinophilia and drug reaction syndrome with systemic symptoms, immune-mediated necrotizing myopathy, severe muscle weakness, ocular myasthenia, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, lupus-like syndrome, muscle rupture, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. Additionally, avoid extremes in temperature, and it is best to store it at room temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets (10 tablets/PTP x 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.